PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.56%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-79.23%
G&A reduction while TRVN shows 18.44% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-99.88%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-74.55%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-74.55%
Both companies reducing total costs. Martin Whitman would check industry trends.
-99.95%
Both companies reducing interest expense. Martin Whitman would check industry trends.
609.47%
D&A growth 50-75% of TRVN's 868.19%. Bruce Berkowitz would examine asset strategy.
90.56%
EBITDA growth exceeding 1.5x TRVN's 12.94%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
74.50%
Operating income growth exceeding 1.5x TRVN's 9.64%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
136.63%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
91.74%
Pre-tax income growth exceeding 1.5x TRVN's 7.40%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-502.21%
Both companies reducing tax expense. Martin Whitman would check patterns.
91.74%
Net income growth exceeding 1.5x TRVN's 7.40%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
91.71%
EPS growth exceeding 1.5x TRVN's 7.42%. David Dodd would verify competitive advantages.
91.71%
Diluted EPS growth exceeding 1.5x TRVN's 7.42%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.